Onkologie. 2018:12(6):267-271 | DOI: 10.36290/xon.2018.048

Breast cancer in elderly

Iveta Kolářová1,2,3, Jaroslav Vaňásek1,2,3,4, Karel Odrážka1,2,3,4,5,6,7, Aleš Hlávka1,3, Jan Štuk1, Lukáš Sákra3, Jana Mergancová3
1 Multiscan, s. r. o., Pardubice
2 Fakulta zdravotnických studií Pardubice, Univerzita Pardubice
3 Nemocnice Pardubického kraje, a. s., Pardubická nemocnice
4 Fakulta vojenského zdravotnictví Hradec Králové, Univerzita obrany, Hradec Králové
5 1. lékařská fakulta UK Praha
6 3. lékařská fakulta UK Praha
7 Katedra radiační onkologie IPVZ Praha

A typical age of the czech patient with breast cancer is 60–69 years. Epidemiological studies confirmed that breast cancer in olderwomen usually had more favorable biological characteristics, such as high percentage of luminal A types. Despite the generalopinion that breast cancer in older age is an indolent disease, there is clearly evidence of higher disease-specific mortality incomparison with younger patients. This fact is probably related to the use of less aggressive drug therapy. In older patients, thetreatment decision should begin with an estimate of life expectancy, an assessment of the general condition, and proceed todiscussion of the benefits and risks of treatment. The problem of treatment in the elderly is that there is little evidence on theoptimal treatment decisions. The American Society of Clinical Oncology guidelines for geriatric oncology were published in 2018.The guidelines provide recommendations on the use of clinical assessment tools and decision making models for older patients.Clinicians should use results of the evaluation when recommending individual therapeutic plan that can be adjusted in the case ofolder patients. In indicated cases, surgery, radiation as well as drug therapy can be modified to become less aggressive. Particularcandidates for less radical therapy are vulnerable patients with a short life expectancy or with favorable biological characteristicsof the tumor.

Keywords: breast cancer, older age, therapy, ASCO guidelines 2018

Published: December 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolářová I, Vaňásek J, Odrážka K, Hlávka A, Štuk J, Sákra L, Mergancová J. Breast cancer in elderly. Onkologie. 2018;12(6):267-271. doi: 10.36290/xon.2018.048.
Download citation

References

  1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2018-10-25]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802 - 8861.
  2. Hornová J, Büchler T. Karcinom prsu u starších žen. Onkologie 2013; 7(5): 221-224.
  3. Anderson WF, Pfeiffer RM, Dores GM, et al. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiology and Prevention Biomarkers, 2006; 15(10): 1899-1905. Go to original source... Go to PubMed...
  4. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. JNCI: Journal of the National Cancer Institute, 2000; 92(7): 550-556. Go to original source... Go to PubMed...
  5. Bastiaannet E, Liefers GJ, de Craen AJM, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast cancer research and treatment, 2010; 124(3): 801-807. Go to original source... Go to PubMed...
  6. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology, 2009; 21(6): 1323-1360. Go to original source... Go to PubMed...
  7. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast cancer research and treatment, 2011; 126(2): 529-537. Go to original source... Go to PubMed...
  8. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Annals of Oncology, 2014; 26(2): 288-300. Go to original source... Go to PubMed...
  9. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The lancet oncology, 2012; 13(4): e148-e160. Go to original source... Go to PubMed...
  10. Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: American Society of Clinical Oncology Guideline for Geriatric Oncology. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2018; 36(22): 2326. Go to original source... Go to PubMed...
  11. Blamey RW, Bates T, Chetty U, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. European Journal of Cancer, 2013; 49(10): 2294-2302. Go to original source... Go to PubMed...
  12. International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006; 24(3): 337-344. Go to original source... Go to PubMed...
  13. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine, 2004; 351(10): 971-977. Go to original source... Go to PubMed...
  14. Martelli G, Miceli R, Costa A, et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: Fifteen year results of a prospective study. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2008; 112(3): 481-488. Go to original source...
  15. Hind D, Wyld L, Beverley CB, et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev, 2006; 1(1). Go to original source... Go to PubMed...
  16. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. Journal of Clinical Oncology, 2013; 31(19): 2382. Go to original source... Go to PubMed...
  17. Dowsett M, Cuzick J, Ingle J, et al. Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology, 2009; 28(3): 509-518. Go to original source... Go to PubMed...
  18. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. Journal of clinical oncology, 2008; 26(12): 1956-1964. Go to original source... Go to PubMed...
  19. Turner N, Zafarana E, Becheri D, et al. Breast cancer in the elderly: which lessons have we learned?. Future oncology, 2013; 9(12): 1871-1881. Go to original source... Go to PubMed...
  20. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine, 2009; 360(20): 2055-2065. Go to original source... Go to PubMed...
  21. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol, 2006; 24(18): 2750-2756. Go to original source... Go to PubMed...
  22. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. Journal of Clinical Oncology, 2009; 27(8): 1177-1183. Go to original source... Go to PubMed...
  23. Albain KS, Barlow WE, Shak S, et al. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer. Lancet Oncol. 2010; 11(1): 55-65. Go to original source... Go to PubMed...
  24. Kizy S, Altman AM, Marmor S, et al. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. Journal of geriatric oncology, 2018. Go to original source... Go to PubMed...
  25. Sparano JA, Gray RJ, Wood WC, et al. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. 2018. Go to original source...
  26. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. Journal of Clinical Oncology, 2007; 25(25): 3808-3815. Go to original source... Go to PubMed...
  27. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. Journal of Clinical Oncology, 2007; 25(25): 3871-3876. Go to original source... Go to PubMed...
  28. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology, 2006; 24(34): 5381-5387. Go to original source... Go to PubMed...
  29. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama, 2006; 295(14): 1658-1667. Go to original source... Go to PubMed...
  30. Königsberg, R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (< 65) and elderly (65) patients. European Journal of Cancer, 2012; 48(16): 2962-2968. Go to original source... Go to PubMed...
  31. Liedtke C, Hess KR, Karn T, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast cancer research and treatment, 2013; 138(2): 591-599. Go to original source... Go to PubMed...
  32. Cheung K, Syed BM, Green AR, et al. Clinical outcome of triple-negative primary breast cancer in older women: Comparison with their younger counterparts. Journal of Clinical Oncology, 2011; 29(15 suppl.): 1057-1057. Go to original source...
  33. Dreyer G, Vandorpe T, Smeets A, et al. Triple negative breast cancer: clinical characteristics in the different histological subtypes. The Breast, 2013; 22(5): 761-766. Go to original source... Go to PubMed...
  34. Wildiers, H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology, 2018; 19(3): 323-336. Go to original source... Go to PubMed...
  35. Chavez-Macgregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal of Clinical Oncology, 2013; 31(33): 4222. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.